-
Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% (SB206) for the Treatment of Molluscum Contagiosum
-
Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% (SB206) for the Treatment of Molluscum Contagiosum
-
Novan Reports Third Quarter 2022 Financial Results and Provides Corporate Update
-
Novan Reports Third Quarter 2022 Financial Results and Provides Corporate Update
-
Mylan deal puts future of its beleaguered EpiPen in spotlight
-
Exclusive: Big Pharma returning to U.S. price hikes in January after pause
-
Novan Provides Business Update via 10-Q, Adopts Incentive Plan and Agrees to CEO Contract
-
Novartis hints at 2018 outlook hike despite drug price freeze
-
Drug industry on tenterhooks as Maryland price-gouging law nears
-
How drugmakers face global push-back on high prices
-
Valeant names Papa CEO after he resigns from Perrigo

